Focused On-demand Library for Bardet-Biedl syndrome 12 protein

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q6ZW61

UPID:
BBS12_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q6ZW61; D3DNX5; Q7Z342; Q7Z482; Q8NAB8

BACKGROUND:
Bardet-Biedl syndrome 12 protein is integral to the TRiC complex, aiding in protein folding and ciliogenesis through its role in the BBSome assembly. It also contributes to adipogenic differentiation, highlighting its importance in cellular structure and function.

THERAPEUTIC SIGNIFICANCE:
The protein's association with Bardet-Biedl syndrome 12, a disorder with a spectrum of clinical features including early-onset obesity and renal malformation, underscores the therapeutic potential of targeting this protein. Understanding the role of Bardet-Biedl syndrome 12 protein could open doors to potential therapeutic strategies, offering hope for interventions that could alleviate or modify the disease's course.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 113 of 8789